Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy

Armed Forces Hospital, Pakistan

Status and phase: Enrolling; Phase 1

Conditions: Hypoxic Ischemic Encephalopathy of Newborn

Treatments: Drug: Citicoline Sodium

Study type: Interventional

Funder types: Other

Identifiers

NCT06522581

Citicoline for HIE

Details and patient eligibility

About

Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births.

Infants afflicted with moderate HIE face a 10% risk of mortality, with surviving individuals encountering a 30% chance of developing disabilities. The prognosis is graver for severe HIE, with a mortality risk of 60%, and nearly all survivors experiencing some form of disability.

Full description

A number of treatment modalities are available but are not clinically effective due to inefficacy and undesirable side effects. Despite therapeutic hypothermia being the sole effective neuroprotector to date, its applicability is limited in certain scenarios, such as gestational age below 36 weeks, birth weight under 2000 g, and initiation beyond 6 hours of age. Therefore, there is a critical need to explore alternative, safe, effective, and accessible neuroprotective therapies, particularly in developing nations.

Citicoline, cytidine 5-diphosphocholine, is an exogenous substance and a product of rate limiting step of phosphatidyl choline synthesis. It has rapid absorption through enteral route where it breaks into cytidine and choline. Citicoline is a favorable recently developed neuroprotector in HIE as it helps to regenerate neuronal cells by inhibiting different steps of ischemic cascade like inhibiting glutamate built up and ROS synthesis increasing dopamine and acetylcholine neurotransmitters, regenerating injured cell membrane and increasing brain plasticity and repair.

In this study, effects of citicoline as a neuroprotector are evaluated in neonates with moderate and severe HIE.

Enrollment: 200 estimated patients

Sex: All

Ages: 1 to 30 days old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. all indoor newborn babies with HIE II and III
2. who have not received therapeutic hypothermia

Exclusion criteria

1. grade I HIE
2. Babies on TH
3. babies whose parents do not give consent for inclusion in study
4. babies with major congential malformations -

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

200 participants in 2 patient groups, including a placebo group

neonates with HIE receiving citicoline

Experimental group

Description:

this arm will include neonates suffering from hypoxic ischemic encephalopathy and who will be given injection citicoline

Treatment:

Drug: Citicoline Sodium

neonates with HIE receiving placebo

Placebo Comparator group

Description:

this arm will include neonates who will be suffering from HIE but will recieve rotuine care in NICU but will not receive injection citicoline

Treatment:

Drug: Citicoline Sodium